Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa

Journal of Oncology Practice

Volumn 5, Issue 2, 2009, Pages 66-70

  Cella, David ^a,b,c,d   Cappelleri, Joseph C ^a,b,c,d   Bushmakin, Andrew ^a,b,c,d   Charbonneau, Claudie ^a,b,c,d   Li, Jim Z ^a,b,c,d   Kim, Sindy T ^a,b,c,d   Chen, Isan ^a,b,c,d   Michaelson, M Dror ^a,b,c,d   Motzer, Robert J ^a,b,c,d  

^a Research and Education   (United States)

^b PFIZER INC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; SUNITINIB;

ADULT; ARTICLE; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; EUROQOL GROUP FIVE DOMAIN SELF REPORT QUESTIONNAIRE; EUROQOL GROUP VISUAL ANALOG SCALE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL SCALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY KIDNEY SYMPTOM INDEX DISEASE RELATED SYMPTOMS SUBSCALE; HAZARD RATIO; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PHASE 3 CLINICAL TRIAL; PREDICTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY;

EID: 70349747089     PISSN: 15547477     EISSN: None     Source Type: Journal    
DOI: 10.1200/JOP.0922004     Document Type: Article

References (23)

1. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996
2. Dharma-Wardene M, Au HJ, Hanson J, et al: Baseline FACT-G score is a predictor of survival for advanced lung cancer. Qual Life Res 13:1209-1216, 2004
3. Efficace F, Biganzoli L, Piccart M, et al: Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40:1021-1030, 2004
4. Lis CG, Gupta D, Granick J, et al: Can patient satisfaction with quality of life predict survival in advanced colorectal cancer? Support Care Cancer 14:1104-1110, 2006
5. Maisey NR, Norman A, Watson M, et al: Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 38:1351-1357, 2002
6. Efficace F, Bottomley A, Coens C, et al: Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer 42:42-49, 2006
7. Fang FM, Liu YT, Tang Y, et al: Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer 100: 425-432, 2004
8. Roychowdhury DF, Hayden A, Liepa AM: Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 21:673-678, 2003
9. Monk BJ, Huang HQ, Cella D, et al: Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 23:4617-4625, 2005
10. Bukowski R, Cella D, Gondek K, et al: Effects of sorafenib on symptoms and quality of life: Results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30:220-227, 2007
11. Bensalah K, Leray E, Fergelot P, et al: Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175:859-863, 2006
12. Choueiri TK, Garcia JA, Elson P, et al: Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543-550, 2007
13. Kwak C, Park YH, Jeong CW, et al: Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. Tumori 93:68-74, 2007
14. Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002
15. Motzer RJ, Bacik J, Schwartz LH, et al: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463, 2004
16. Suppiah R, Shaheen PE, Elson P, et al: Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107: 1793-1800, 2006
17. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356;115-124, 2007
18. Cella D, Li JZ, Cappelleri JC, et al: Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: Results from a phase III randomized trial. J Clin Oncol 26:3763-3769, 2008
19. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
20. Cella D, Yount S, Du H, et al: Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 4:191-199, 2006
21. de Boer AG, van Lanschot JJ, Stalmeier PF, et al: Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res 13:311-320, 2004
22. EuroQol: A new facility for the measurement of health-related quality of life - The EuroQol Group. Health Policy 16:199-208, 1990
23. Kleinbaum DG, Klein M: Survival Analysis: A Self-Learning Text (ed 2). New York, NY, Springer, 2005